Biotech | November 12, 2021
Ronapreve gets the green light from CHMP to treat non-hospitalised Covid-19 patients
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
According to WHO, over 1.5 million people died of TB in 2020
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
This work has been published in the journal ‘ACS applied materials and interface’
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
Subscribe To Our Newsletter & Stay Updated
